Objectives: This study retrospectively compares the effectiveness of methylprednisolone to
dexamethasone in patients with severe acute respiratory syndrome coronavirus 2 (SARS …

Background The efficacy and safety of methylprednisolone in mechanically ventilated
patients with acute respiratory distress syndrome resulting from coronavirus disease 2019 …

Background Recent trials with dexamethasone and hydrocortisone have demonstrated
benefit in patients with coronavirus disease 2019 (COVID‐19). Data on methylprednisolone …

Background Dysregulated systemic inflammation is the primary driver of mortality in severe
coronavirus disease 2019 (COVID-19) pneumonia. Current guidelines favour a 7–10-day …

Background Corticoid therapy has been recommended in the treatment of critically ill
patients with COVID-19, yet its efficacy is currently still under evaluation. We investigated the …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with diffuse lung
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …

Purpose Dexamethasone is the only drug that has consistently reduced mortality in patients
with COVID-19, especially in patients needing oxygen or invasive mechanical ventilation …

Background: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage.
Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce …

ABSTRACT BACKGROUND: Dexamethasone, a synthetic glucocorticoid, has anti-
inflammatory and immunosuppressive properties. There is a hyperinflammatory response …

Background: There is still no clinical evidence available to support or to oppose
corticosteroid treatment for coronavirus disease 2019 (COVID-19) pneumonia. Objective: To …